Own experience of "Glicifon" using as a local chemotherapy drug for the patients with basal-cell head&neck carcinoma

Author:

Reshetov D. N.1ORCID

Affiliation:

1. Clinical Hospital RZD-Medicine; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Abstract

Introduction. Skin cancer is the most common type among the cancer statistics. It accounts up to 14.2 % of all types of cancer. Basal cell cancer (BCC) is the most common among the skin cancers. Despite the possibilities of using different types of treatment BCC the long-term results are infavorable-the relapse rates are still high and cosmetic results are unsufficient. Using the local chemotherapy is alternative method of head&neck BCC treatment.The study objective. Efficency analysis of using «Glycifon» as a local chemotherapy drug for head&neck BCC. Materials and methods. The study included 24 patients with head&neck BCC who underwent local chemotherapy with "Glycifon" drug. 18 (75 %) patients had primary tumors, 6 (25 %) - relapsed tumors. 7 (29.2 %) patients had multicentre BCC. All patients received local chemotherapy by "Glycifon" according to recommended instructions.Results. 79.2 % of patients had full regress of BCC after "Glycifon" local chemotherapy. Medium follow up time was 11.5 month. 2 patients (8.35) had to interrupt the treatment but for the intensive pain after the drug application. Other patients finished the therapy satisfactorily. No toxic reactions were observed. Inflammatory reactions in application zones were moderate and easily fixed. All patients who finished the therapy (100 %) we satisfied about the cosmetic results.Conclusion. Usage of "Glycifon" drug for local chemotherapy of head&neck DCC is effective, safe and cosmetic satisfied method. Possibility of using "Glycifon" in ambulatory treatment reduce the total medical & economic costs.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference13 articles.

1. State of cancer care in Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shahzadova. Moscow: P.A. Herzen MORI - branch of the NMRRC of the Ministry of Health of Russia, 2020 (In Russ.).

2. Volgin V.N., Sokolova T.V., Kolbina M.S., Sokolovskaya A.A. Basalioma: diagnostics, treatment(part 2). Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology 2013;(2):16—23. (In Russ.).

3. Zalyalyutdinova L.N., Garaev R.S. The Russian drug glyciphon, an organophosphorus epoxides for the treatment of basal cell carcinoma — clinical and experimental studies. Opukholi golovy i shei = Head and Neck Tumors 2015;5(3):31—8. (In Russ.).

4. Molochkov V.A., Snarskaya Ye.S., Polyakov P.Yu. to the treatment of skin basaliomas. ossiysky zhurnal kozhnykh i venericheskikh bolezney = Russian Journal of Skin and Venereal Diseases 2005;6:4—9. (In Russ.).

5. Podvyaznikov S.O. Experience in local Glyciphon chemotherapy of basal cell carcinoma of the problem face areas. Opukholi golovy i shei = Head and Neck Tumors 2017;7(1):22—5. (In Russ.)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3